Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04.
Conference Journal of Clinical Oncology · June 1, 2026 TPS11202Background: Patients with advanced or metastatic HER2 IHC 3+ solid tumors hav ... Full text CiteSymbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
Conference Journal of Clinical Oncology · June 1, 2026 TPS3675Background: Multi-agent chemotherapy regimens (eg, mFOLFOX6) ± anti-vascular e ... Full text CiteAbstract CT184: Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optimization in microsatellite stable colorectal cancer (MSS CRC) without liver, bone, or brain metastasis (BBOpCo)
Conference Cancer Research · April 17, 2026 AbstractPatients (pts) with metastatic (met) MSS CRC are treated with sequential lines of chemotherapy (chemo), but most experience progression and prolonged toxicities during their disease course. BOT is ... Full text CiteRecent Grants
AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal C
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2026 - 2031An Interventional Phase 3 Double Blind Randomized Study to Evaluate the Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Bevacizumab in Combination with Chemotherapy in Treatment-Naive Participants with Metastatic Colorectal
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2026 - 2031Optimizing Body Mass Index (BMI) with TCMCB07 in Patients with Newly Diagnosed Metastatic Colore
Clinical TrialPrincipal Investigator · Awarded by Endevica Bio · 2025 - 2030View All Grants
Education
Maulana Azad Medical College (India) ·
2011
M.B.B.S.